Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Stomatitis 1Lung Neoplasms 1Head and Neck Neoplasms 1Fatigue 1Cachexia 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × clazakizumab × Clear all
NCT01403064 2021-05-11

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

CSL Behring

Phase 2 Terminated
76 enrolled 25 charts
Head & Neck

Head and Neck Neoplasms, Stomatitis

NCT00866970 2020-07-09

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

CSL Behring

Phase 2 Completed
124 enrolled
Thoracic

Cachexia, Fatigue, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡